Moderna stock jumps after FDA reverses course on flu shot
Shares of Moderna MRNA rose 6% on Wednesday after the company announced that the FDA agreed to review its regulatory filing seeking approval for its seasonal influenza vaccine, mRNA-1010. A final decision is expected by Aug. 5, 2026. This announcement...
Zacks.com